EFFECT OF HYOSCINE BUTYLBROMIDE (BUSCOPAN) AS CERVICAL SPASMOLYTIC AGENT IN LABOUR

Sree Ramya Narappagari\textsuperscript{1}, Himabindu\textsuperscript{2}

\textsuperscript{1}Postgraduate, Department of Obstetrics and Gynaecology, RGGWCH, Puducherry.
\textsuperscript{2}Associate Professor, Department of Obstetrics and Gynaecology, IGMCRI, Puducherry.

ABSTRACT

BACKGROUND
Progression of labour requires effective cervical dilatation and effacement in addition to good uterine contractions. A commonly available spasmolytic namely Buscopan (Hyoscine-N-butylbromide, HBB) is known to inhibit smooth muscle contraction in the cervix and thus enhance cervical dilatation in labour. In the present study, outcome of labour after usage of Hyoscine is studied.

RESULTS
Among primigravidae, the mean duration of active phase of labour in Buscopan group and control group is found to be 114 and 182 minutes respectively \((p \text{ value} < 0.002 \text{ highly significant})\). Among multigravidae, the duration was found to be 89 minutes and 113 minutes respectively in Buscopan group and control group \((\text{statistically insignificant with } p \text{ value of 0.27})\). No significant difference was observed in the duration of second and third stage of labour, mode of delivery, birth weight, Apgar score and colour of liquor in both the groups. A percentage change of pain score after 2 hours in both the groups is noted. Statistical analysis was done by using SPSS software version 19.0. \(P\) value of <0.05 is taken as significant.

CONCLUSION
Effective shortening of the duration of labour and pain relief can be achieved without any significant detrimental effects on the mother or the foetus.

KEYWORDS
Cervical Dilatation, Active Phase of Labour, Buscopan, Pain Score.


FINANCIAL OR OTHER COMPETING INTEREST: None.

CONTACT:
Sree Ramya Narappagari, 12/643, Kota Street, Proddatur-516360, Andhra Pradesh.
E-mail: ramyanarreddy@gmail.com
DOI: 10.14260/Jemds/2016/1509
studies have been carried out to evaluate the role of Buscopan as an analgesic.\(^8\)

The present study was conducted in order to determine whether Buscopan shortens the first stage of labour, to evaluate its efficacy as an analgesic and to study the incidence of maternal and neonatal complications, following its usage.

**MATERIALS AND METHODS**

A prospective comparative study was undertaken in RGGWCH, Pondicherry, from December 2014 to November 2015. Ethical clearance (IEC) was obtained from the institute’s ethical committee prior to the study. Fullterm pregnant women satisfying the inclusion and exclusion criteria admitted in active labour in RGGWCH, Pondicherry during the study period who gave informed consent were taken in the study. For every patient in the study group, age and parity matched next patient was taken as control for that case.

**Inclusion Criteria**

Women with
1. Normal singleton pregnancy.
2. Pregnancy at 37-41 weeks.
3. Vertex presentation.
4. Active labour.

**Exclusion Criteria**

Women with
1. Previous uterine scar.
2. Malpresentation.
3. Cephalopelvic disproportion.
4. Antepartum haemorrhage.
5. Twin pregnancy.

In both groups, active management of labour was carried out in the form of amniotomy once patient entered active phase of labour (>3 cm). Oxytocin infusion was used if uterine contractions were not effective. Injection Tramadol 50 mg IM was given for all patients uniformly at recruitment.

**In Group-A (Buscopan)**

Hyoscine butylbromide 20 mg diluted with distilled water up to 10 cc was given slowly intravenously.

**In Group-B (Control)**

10 mL normal saline was given at the same rate intravenously. Participants received the contents as a single dose, intravenously when they were assessed and recruited into the study. The progress of the participants was closely documented by the principal investigator till delivery. The conduct of labour and delivery for both the cases and control groups was in accordance with labour ward protocol of the institute.

Women in both the groups were asked to mark pain they felt at the point of recruitment into the study and 2 hours later using visual analogue scale. Per vaginal examination was repeated at 4 hours and 8 hours duration after entry into the study. Partographic evaluation for the rate of cervical dilatation in the first stage and followed for the duration of the second stage, third stage of labour, caesarean section rate, assessment of blood loss and APGAR score for the neonates were noted. Intervention through instrumentation or caesarean section was by the usual obstetric determinants.

Based on the VAS, percentage change in pain from baseline is recorded. Percentage pain relief is the difference in pain score just before treatment and pain score two hours later.

The primary outcomes studied were the rate of cervical dilatation, duration of first stage and percentage change in pain. The secondary outcome measures compared were the duration of second stage of labour, mode of delivery, neonatal outcome and any side effects of the drug.

![Visual Analogue Scale](image)

**Figure 1. Visual Analogue Scale used in the Present Study**

**RESULTS**

The observations of the study were analysed. Under both the groups, there were uniformity of cases with regard to mean age, period of gestation and parity.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Buscopan Group</th>
<th>Control Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>24.62±3.53</td>
<td>24.67±3.91</td>
</tr>
<tr>
<td>Period of gestation</td>
<td>39.1±2.1</td>
<td>39.1±0.89</td>
</tr>
<tr>
<td>Primigravida</td>
<td>60</td>
<td>59</td>
</tr>
<tr>
<td>Multigravida</td>
<td>40</td>
<td>41</td>
</tr>
<tr>
<td>Oxytocin acceleration</td>
<td>24%</td>
<td>20%</td>
</tr>
</tbody>
</table>

Among primigravidae who received Buscopan, the mean duration of active phase of labour was 114 minutes which is very less compared to the duration in control group of 182 minutes. This decrease in duration is found to be highly statistically significant with p value < 0.002. The rate of cervical dilatation among primigravidae was 4.7 cm/hour and 3 cm/hour in Buscopan and control groups respectively.

The mean duration of active phase of labour in multigravidae was found to be 89 minutes and 113 minutes respectively in Buscopan group and control group. However, this decrease in the duration was found to be statistically insignificant with p value of 0.27. The rate of cervical dilatation in these women was calculated to be 5.3 cm/hour and 4 cm/hour which is statistically just significant.

![Active phase duration in both groups](image)

**Active phase duration in both groups (pri and multi)**
In Buscopan group, a percentage chance of pain by 17% was observed which was statistically significant (p < 0.001). No serious side effects were observed in both the groups. Transient side effects like maternal and foetal tachycardia were observed in few cases. But no adverse effects on the mother and the foetus were observed in these cases.

The mean duration of second stage of labour in Buscopan group was higher than the control group (9.2±4 minutes vs. 8±3 minutes), this difference was not statistically significant (p >0.05). Since per vaginal examinations were done once in 4 hours in the study population, the second stage was shorter than anticipated in many cases. The mean duration of third stage of labour in cases and controls was 9±3.5 and 9±3 minutes respectively. This is statistically not significant (p >0.05).

There was no significant difference in the mode of delivery, birth weight, Apgar score and colour of the liquor in both the groups.

<table>
<thead>
<tr>
<th>Mode of Delivery</th>
<th>Buscopan Group</th>
<th>Control Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>Normal vaginal delivery</td>
<td>90</td>
<td>90%</td>
</tr>
<tr>
<td>Instrumental vaginal delivery</td>
<td>3</td>
<td>3%</td>
</tr>
<tr>
<td>LSCS</td>
<td>7</td>
<td>7%</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>100%</td>
</tr>
</tbody>
</table>

Table 1. Mode of Delivery

χ²= 1.27 df = 3 p = 0.73 Not significant

<table>
<thead>
<tr>
<th>Indication for Operative Interference</th>
<th>Buscopan Group</th>
<th>Control Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>Cervical dystocia</td>
<td>1</td>
<td>1%</td>
</tr>
<tr>
<td>Maternal exhaustion</td>
<td>1</td>
<td>1%</td>
</tr>
<tr>
<td>Foetal distress</td>
<td>3</td>
<td>3%</td>
</tr>
<tr>
<td>Failure to descent</td>
<td>5</td>
<td>5%</td>
</tr>
<tr>
<td>No operative interference</td>
<td>90</td>
<td>90%</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>100%</td>
</tr>
</tbody>
</table>

Table 2

Side Effects
Maternal tachycardia was observed in one case. Foetal tachycardia was observed in three cases, but there was no variation in the neonatal outcome observed in these cases. Those women who had any side effects like foetal tachycardia in the study group were managed according to labour room protocol of the Institute. The side effects observed were transient.

DISCUSSION
Modern Obstetricians are now in search of new drugs, which have got the sole beneficiary effect on the dilatation of the internal os with minimal side effects on foetus and the mother. One such antispasmodic drug is Hyoscine butylbromide which has been used to shorten the duration of labour. HBB has been used in obstetric practice for many years.

Several studies, which included both primigravid and multigravid women, have been carried out to evaluate the effect of Buscopan on cervical dilatation. Corsen3 (1953) studied the various uses and modes of action of HBB in Obstetrics and found that most prompt action occurred with intravenous and suppository routes. No significant side effects occurred with up to 30 mg dose.

Tiwari K et al4 (2003) studied the effectiveness of Buscopan and Valethamate bromide on cervical dilatation with 300 cases using Buscopan intravenously with 40 mg dose as two divided doses. Significant shortening of the first stage of labour was noted with Buscopan and Valethamate bromide with more marked shortening in Buscopan group. Sirohiwal, Dahiya and De5 (2005) studied the efficacy of Buscopan rectal suppositories as cervical spasmyotics in labour.

Our study population included 200 patients; of which 100 were controls and remaining 100 were cases. The mean age distribution and period of gestation of our present study was comparable to the other studies. In the present study, both primi and multigravidae are included and the rate of cervical dilatation analysed separately. Majority of the studies had recruited cases for Buscopan at 3-4 cm of cervical dilatation as it indicates the onset of active phase of labour similar to our study.

The mean duration of active phase of labour in study by Gandhi and Sharma et al9 was 144.3±19.7 minutes (vs. 208.7 min. in controls) and this was comparable with our study. Kirim SA et al10 in their study reported the mean duration of active phase as 159.3±40.9 minutes (vs. 299±86 min.).

Comparison of the Duration of Active Phase among Primigravidae in Various studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Buscopan Group (min.)</th>
<th>Control Group (min.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aggarwal et al7</td>
<td>226</td>
<td>496</td>
</tr>
<tr>
<td>Kirim Set al10</td>
<td>191.1±43.06</td>
<td>248.21±66.16</td>
</tr>
<tr>
<td>Al-Khishali et al13</td>
<td>167.7±76.2</td>
<td>193.8±58</td>
</tr>
<tr>
<td>Samuels LA et al6</td>
<td>176</td>
<td>258</td>
</tr>
<tr>
<td>Maria Aziz 12</td>
<td>205</td>
<td>263</td>
</tr>
<tr>
<td>Al Quahatani et al13</td>
<td>165</td>
<td>215</td>
</tr>
<tr>
<td>Makvandi S et al14</td>
<td>141±81.7</td>
<td>230±61.9</td>
</tr>
<tr>
<td>Present study</td>
<td>114±75</td>
<td>182±88</td>
</tr>
</tbody>
</table>

Comparison of Duration of active Phase among Multigravidae in Various Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Buscopan Group (min.)</th>
<th>Control Group (min.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kirim S et al10</td>
<td>170.1±50.87</td>
<td>224±53.76</td>
</tr>
<tr>
<td>Al-Khishali et al11</td>
<td>90.1±37.9</td>
<td>195.6±72</td>
</tr>
<tr>
<td>Samuels LA et al6</td>
<td>137</td>
<td>200</td>
</tr>
<tr>
<td>Maria Aziz 12</td>
<td>106</td>
<td>205</td>
</tr>
<tr>
<td>Seldhavat L et al15</td>
<td>186</td>
<td>260</td>
</tr>
<tr>
<td>Present study</td>
<td>89±50</td>
<td>113±40</td>
</tr>
</tbody>
</table>

All the above studies found that the mean duration of active phase of labour was reduced by Buscopan compared to control group. The reduction in the mean duration of first stage of labour with the use of Buscopan has been found consistently in all these studies. The mean duration of first stage of labour in our study was least compared to the other studies. This is probably because of active management of labour in our study. The difference in the mean duration of active phase of labour between Buscopan and control group in our study was statistically significant.

The rate of cervical dilatation in primigravida in present study is 4.7±2.2 cm/hour and 3.1±1.9 cm/hour in Buscopan and control group. Majority of the women (41.7 vs. 22%) had a rate of cervical dilatation of 3-4 cm/hour.

In study by Makvandi S et al, the cervical dilatation rate was found to be 2.6 cm/hour in primi study group & 1.5 cm/hour in primi control group. In the study by Maria A, the cervical dilatation rate was 2.04 cm/hour in primi study group and 1.5 cm/hour in primi control group. In the Baracho et al study, the cervical dilatation rates were 1.85 cm/hour in primi study group and 1.35 cm/hour in primi control group.

In contrast to our study, Gupta Bet al found that the active phase duration and rate of cervical dilatation in the group that received HBB (3.9±2.2 hours) were not significantly different from the control group (3.6±2.04 hours). Similar observations were made by Aldahhan FH et al who demonstrated duration of active phase in cases (246 min.) to be significantly longer compared to that in controls (204 min.) which is in contrast to the present study.

The mean duration of second stage of labour in the present study was 9±4 min. and 8±3 min. in Buscopan group and control group respectively. This difference was not statistically significant. Sameuls LA et al found the mean duration of second stage labour in Buscopan and control group to be 20 min. and 15 min. respectively with no significant decrease in duration. This is comparable to the present study. In the study by Sekhavath et al, the mean duration of second stage labour in Buscopan group was 20 min. vs. 25.8 min. in control group without significant decrease. Aldahhan FH et al in their study found the mean duration of second stage labour to be 15.6 min. and 12.7 min. in Buscopan and control group respectively, thus showing no decrease of duration.

In the present study, a mean percentage change in pain score of 17% was observed in Buscopan group which is comparable with that observed in study by Aggarwal et al. However, a percentage change in pain of 12% was observed in control group also which may be explained as pain being a subjective component and many factors like personal pain threshold, pre-existing psychological problems and kind of support affect its assessment. Aggarwal et al in their study showed a percentage change of pain in Buscopan group by 35.6% in comparison with their control group decrease of pain by 12.5%. This study has used the visual analogue scale and calculated the percentage decrease of pain as in the present study. In a study by Fardizar Z et al, the need for analgesic has decreased by 20% in Buscopan group compared to the control group.

CONCLUSION
Acceleration of labour is considered to be an important factor in reducing maternal morbidity as well as neonatal complications. Various forms of pharmacological intervention have helped in shortening the duration of labour by augmenting cervical dilatation making child birth safe. One such drug is Buscopan, which by its spasmolytic action helps in cervical dilatation and additionally considered to decrease pain.

The following Conclusions were drawn from the study
1. Buscopan is effective in reducing the duration of active phase of labour especially in primigravidae.
2. There is significant improvement in the rate of cervical dilatation with administration of Buscopan in both primi and multigravidae.
3. Buscopan also has significant effect on reducing the pain in labour.
4. There is no significant variation in the duration of second and third stage of labour with use of Buscopan.
5. Transient side effects like foetal tachycardia observed in few women due to Buscopan but with no untoward effect on the mother or the newborn. There is no difference in the mode of delivery with use of Buscopan.

Thus, effective shortening of the duration of labour and pain relief can be achieved without any significant detrimental effects on the mother or the foetus. Hence, it can be better recommended for use in modern obstetrics to relieve spasm and to hasten the rate of cervical dilatation.

Limitations of the Study
1. Since this study was not a double blinded study and without randomisation subjective variation in the observations noted may be present.
2. Assessing subjective component like pain is not always accurate as it is influenced by many confounding factors like personal pain threshold, psychological factors and socioeconomic status.
3. The period of study is short, hence many outcomes like longterm neurodevelopmental outcomes and maternal side effects may not have surfaced.

Hence, well-designed randomised double blind control studies are recommended further for improving level of evidence.

REFERENCES